Abstract
Conjunctival tumors may be some of the prominent manifestations of systemic inherited diseases. In such instances, ophthalmologists should recognize the systemic association and initiate appropriate systemic and genetic evaluation. Conjunctival tumors and tumor-like conditions with syndromic association can be considered under the categories of pigmented lesions (Peutz–Jeghers syndrome), benign tumors (Goldenhar syndrome), malignant tumors (xeroderma pigmentosum), and amyloidosis (Table 22.1). We will briefly review such conjunctival lesions and the associated systemic disorders. Other entities may also have associated eyelid tumors and are covered in detail elsewhere (see Chaps. 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11). Where applicable, inheritance patterns of the syndromic association and molecular genetics are also included.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Carney JA, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985;64(4):270–83.
Kennedy RH, Waller RR, Carney JA. Ocular pigmented spots and eyelid myxomas. Am J Ophthalmol. 1987;104(5):533–8.
Rothenbuhler A, Stratakis CA. Clinical and molecular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab. 2010;24(3):389–99.
Peutz JLA. On a very remarkable case of familial polyposis of the mucous membrane of the intestinal tract and nasopharynx accompanied by peculiar pigmentations of the skin and mucous membrane. Ned Tijdschr Geneeskd. 1921;10:839–47.
Jeghers H, Mc KV, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med. 1949;241(26):1031–6.
Jenne DE, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998;18(1):38–43.
Hearle N, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209–15.
Traboulsi EI, et al. Pigmented ocular fundus lesions in the inherited gastrointestinal polyposis syndromes and in hereditary nonpolyposis colorectal cancer. Ophthalmology. 1988;95(7):964–9.
Traboulsi EI, Maumenee IH. Periocular pigmentation in the Peutz-Jeghers syndrome. Am J Ophthalmol. 1986;102(1):126–7.
Giardiello FM, Offerhaus JG. Phenotype and cancer risk of various polyposis syndromes. Eur J Cancer. 1995;31A(7–8):1085–7.
Beggs AD, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59(7):975–86.
Happle R. The group of epidermal nevus syndromes Part I. Well defined phenotypes. J Am Acad Dermatol. 2010;63(1):1–22, quiz 23–4.
Lin H, Yan J. Linear nevus sebaceous syndrome in a patient with atypical associated abnormalities. J Pediatr Ophthalmol Strabismus. 2010;47 Online:e1–4.
Goldenhar M. Associations malformatives de l'oeil et de l'oreille: en particulier, le syndrome: dermoide epibulbaire-appendices auriculaires – fistula auris congenita et ses relations avec la dysostose mandibulo-faciale. J Genet Hum. 1952;1:243–82.
Gorlin RJ, et al. Oculoauriculovertebral dysplasia. J Pediatr. 1963;63:991–9.
De Golovine S, et al. Goldenhar syndrome: a cause of secondary immunodeficiency? Allergy Asthma Clin Immunol. 2012;8(1):10.
Tasse C, et al. A family with autosomal dominant oculo-auriculo-vertebral spectrum. Clin Dysmorphol. 2007;16(1):1–7.
Grabb WC. The first and second branchial arch syndrome. Plast Reconstr Surg. 1965;36(5):485–508.
Wang R, Martinez-Frias ML, Graham Jr JM. Infants of diabetic mothers are at increased risk for the oculo-auriculo-vertebral sequence: a case-based and case–control approach. J Pediatr. 2002;141(5):611–7.
Baum JL, Feingold M. Ocular aspects of Goldenhar’s syndrome. Am J Ophthalmol. 1973;75(2):250–7.
Velez G. Duane’s retraction syndrome associated with Goldenhar’s syndrome. Am J Ophthalmol. 1970;70(6):945–6.
Nijhawan N, et al. Caruncle abnormalities in the oculo-auriculo-vertebral spectrum. Am J Med Genet. 2002;113(4):320–5.
Margolis S, et al. Retinal and optic nerve findings in Goldenhar-Gorlin syndrome. Ophthalmology. 1984;91(11):1327–33.
Rollnick BR, et al. Oculoauriculovertebral dysplasia and variants: phenotypic characteristics of 294 patients. Am J Med Genet. 1987;26(2):361–75.
Kallen K, et al. Relation between oculo-auriculo-vertebral (OAV) dysplasia and three other non-random associations of malformations (VATER, CHARGE, and OEIS). Am J Med Genet A. 2004;127(1):26–34.
Lindhurst MJ, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med. 2011;365(7):611–9.
Cohen Jr MM, Hayden PW. A newly recognized hamartomatous syndrome. Birth Defects Orig Artic Ser. 1979;15(5B):291–6.
Wiedemann HR, et al. The proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. Eur J Pediatr. 1983;140(1):5–12.
Happle R. Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J Am Acad Dermatol. 1987;16(4): 899–906.
Nguyen D, et al. Cutaneous manifestations of proteus syndrome: correlations with general clinical severity. Arch Dermatol. 2004;140(8):947–53.
Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22(3):183–98.
Turner JT, Cohen Jr MM, Biesecker LG. Reassessment of the Proteus syndrome literature: application of diagnostic criteria to published cases. Am J Med Genet A. 2004;130(2):111–22.
Bouzas EA, et al. Ophthalmologic examination in the diagnosis of Proteus syndrome. Ophthalmology. 1993;100(3):334–8.
De Becker I, et al. Ocular manifestations in Proteus syndrome. Am J Med Genet. 2000;92(5):350–2.
Sheard RM, Pope FM, Snead MP. A novel ophthalmic presentation of the Proteus syndrome. Ophthalmology. 2002;109(6):1192–5.
Biesecker LG, et al. Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. Am J Med Genet. 1999;84(5):389–95.
Schimke RN, et al. Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas. A possible regulatory defect in the differentiation of chromaffin tissue. N Engl J Med. 1968;279(1):1–7.
Morrison PJ, Nevin NC. Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome). J Med Genet. 1996;33(9):779–82.
Eng C, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 1994;3(2):237–41.
Jacobs JM, Hawes MJ. From eyelid bumps to thyroid lumps: report of a MEN type IIb family and review of the literature. Ophthal Plast Reconstr Surg. 2001;17(3):195–201.
Eter N, et al. Typical ocular findings in a patient with multiple endocrine neoplasia type 2b syndrome. Graefes Arch Clin Exp Ophthalmol. 2001;239(5):391–4.
Robertson DM, Sizemore GW, Gordon H. Thickened corneal nerves as a manifestation of multiple endocrine neoplasia. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1975;79(6):OP772–87.
Gomez JM, et al. Neuromas and prominent corneal nerves without MEN 2B. Ann Endocrinol (Paris). 1998;59(6):492–4.
Riley Jr FC, Robertson DM. Ocular histopathology in multiple endocrine neoplasia type 2b. Am J Ophthalmol. 1981;91(1):57–64.
Spector B, Klintworth GK, Wells Jr SA. Histologic study of the ocular lesions in multiple endocrine neoplasia syndrome type IIb. Am J Ophthalmol. 1981;91(2):204–15.
O’Riordain DS, et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery. 1994;116(6):1017–23.
Pacini F, et al. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):475–85.
Eng C, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575–9.
Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol. 1987;123(2):241–50.
Lehmann AR, McGibbon D, Stefanini M. Xeroderma pigmentosum. Orphanet J Rare Dis. 2011;6:70.
Cleaver JE. Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum. J Dermatol Sci. 2000;23(1):1–11.
Kraemer KH, et al. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol. 1994;130(8):1018–21.
Wattendorf DJ, Kraemer KH. Xeroderma pigmentosum. Seattle: University of Washington; 2005.
Cleaver JE, et al. Increased ultraviolet sensitivity and chromosomal instability related to P53 function in the xeroderma pigmentosum variant. Cancer Res. 1999;59(5):1102–8.
Dollfus H, et al. Ocular manifestations in the inherited DNA repair disorders. Surv Ophthalmol. 2003;48(1):107–22.
Johnson MW, et al. Malignant melanoma of the iris in xeroderma pigmentosum. Arch Ophthalmol. 1989;107(3):402–7.
Ramkumar HL, et al. Ophthalmic manifestations and histopathology of xeroderma pigmentosum: two clinicopathological cases and a review of the literature. Surv Ophthalmol. 2011;56(4):348–61.
Sipe JD, Cohen AS. Amyloidosis. In: Kasper DL et al., editors. Harrison’s principles of internal medicine. New York: McGraw-Hill Inc; 2005.
Shields JA, et al. Systemic amyloidosis presenting as a mass of the conjunctival semilunar fold. Am J Ophthalmol. 2000;130(4):523–5.
Sandgren O. Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement. Surv Ophthalmol. 1995;40(3):173–96.
Westermark P, et al. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid. 2005;12(1):1–4.
Landa G, et al. Eyelid bleeding and atypical amyloidosis. Am J Ophthalmol. 2004;138(3):495–6.
Brownstein MH, Elliott R, Helwig EB. Ophthalmologic aspects of amyloidosis. Am J Ophthalmol. 1970;69(3):423–30.
Knowles 2nd DM, et al. Amyloidosis of the orbit and adnexae. Surv Ophthalmol. 1975;19(6):367–84.
Purcell Jr JJ, et al. Conjunctival involvement in primary systemic nonfamilial amyloidosis. Am J Ophthalmol. 1983;95(6):845–7.
Taban M, et al. Review: orbital amyloidosis. Ophthal Plast Reconstr Surg. 2004;20(2):162–5.
Marcet MM, et al. Localized orbital amyloidosis involving the lacrimal sac and nasolacrimal duct. Ophthalmology. 2006;113(1):153–6.
Dinakaran S, Singh AD, Rennie IG. Orbital amyloidosis presenting as ptosis. Eye (Lond). 2005;19(1):110–2.
Shalchi Z, Taylor SR, Lightman S. The eye in haematological disease. Br J Hosp Med (Lond). 2011;72(12):691–7.
Hitchings RA, Tripathi RC. Vitreous opacities in primary amyloid disease. A clinical, histochemical, and ultrastructural report. Br J Ophthalmol. 1976;60(1):41–54.
Savage DJ, Mango CA, Streeten BW. Amyloidosis of the vitreous. Fluorescein angiographic findings and association with neovascularization. Arch Ophthalmol. 1982;100(11):1776–9.
Lachmann HJ, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–71.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Xu, L.T., Singh, A.D., Traboulsi, E.I. (2014). Systemic Associations. In: Pe'er, J., Singh, A. (eds) Clinical Ophthalmic Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38336-6_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-38336-6_22
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-38335-9
Online ISBN: 978-3-642-38336-6
eBook Packages: MedicineMedicine (R0)